Frameworks for the Future: Implementing FDA Guidance on Artificial Intelligence in Biopharma

Read full text Summarise with VIRAT
Authors: Kishore Raju Vatsavai, Jayaram Kamma, Anil Kumar Ramgiri, Kishore Kumar Hotha
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Artificial Intelligence (AI) is transforming the pharmaceutical industry, from early drug discovery to post-market surveillance. The recent Food and Drug Administration (FDA) draft guidance “Artificial Intelligence in Drug and Biological Product Development”—outlines regulatory expectations for AI/ML in drug development, emphasizing transparency, reliability, and human oversight. This article compiles insights from regulatory discussions, technical literature, and real-world applications to examine how AI speeds up innovation while introducing new challenges. It highlights key opportunities in R&D, clinical development, manufacturing, and quality assurance, and discusses the future path for pharma and biotech organizations striving to responsibly incorporate AI into their operations.

Fields of Study & Subjects

Artificial Intelligence in Healthcare and Education Computational Drug Discovery Methods Artificial Intelligence Applications

Publication details

Journal / source
American Journal of Analytical Chemistry
Volume
17
Issue
03
Pages
45–60
Publication date
1 January 2026
Language
EN